NTLA vs. CRSP

In the year-to-date period, NTLA achieves a -60.05% return, which is significantly lower than CRSP's -34.95% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NTLA Sharpe Ratio is -0.96, which is lower than the CRSP Sharpe Ratio of -0.66. The chart below compares the historical Sharpe Ratios of NTLA and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NTLA nor CRSP has paid dividends to shareholders.

The maximum NTLA drawdown since its inception was -93.20%, which is greater than CRSP's maximum drawdown of -81.61%. Use the drawdown chart below to compare losses from any high point for NTLA and CRSP. For additional features, visit the drawdowns tool.

Intellia Therapeutics, Inc. (NTLA) and CRISPR Therapeutics AG (CRSP) have volatilities of 19.57% and 19.01%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.